Correction to: Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway
- 370 Downloads
Correction to: Investigational New Drugs (2018) 36:743–754
The authors would like to note an omission of disclosure in this paper. Author JDS is cofounder, equity-holder, and consultant of GILTRx Therapeutics.
© Springer Science+Business Media, LLC, part of Springer Nature 2019